Collagen proline hydroxylase inhibitor-1CAS# 223663-32-9 |
2D Structure
- Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium
Catalog No.:BCC4600
CAS No.:168555-66-6
- Eribulin
Catalog No.:BCC5174
CAS No.:253128-41-5
- Eribulin mesylate
Catalog No.:BCC5173
CAS No.:441045-17-6
- CYT997 (Lexibulin)
Catalog No.:BCC4601
CAS No.:917111-44-5
- MPC 6827 hydrochloride
Catalog No.:BCC8040
CAS No.:917369-31-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 223663-32-9 | SDF | Download SDF |
PubChem ID | 9911272 | Appearance | Powder |
Formula | C24H21N5O4 | M.Wt | 443.45 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO | ||
Chemical Name | 8-(4-benzylpiperazine-1-carbonyl)-3-nitro-1H-1,10-phenanthrolin-4-one | ||
SMILES | C1CN(CCN1CC2=CC=CC=C2)C(=O)C3=CN=C4C(=C3)C=CC5=C4NC=C(C5=O)[N+](=O)[O-] | ||
Standard InChIKey | HPDVDDAVQSIBPH-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H21N5O4/c30-23-19-7-6-17-12-18(13-25-21(17)22(19)26-14-20(23)29(32)33)24(31)28-10-8-27(9-11-28)15-16-4-2-1-3-5-16/h1-7,12-14H,8-11,15H2,(H,26,30) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Collagen proline hydroxylase inhibitor-1 is an antifibroproliferative agents. |
Collagen proline hydroxylase inhibitor-1 Dilution Calculator
Collagen proline hydroxylase inhibitor-1 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.255 mL | 11.2752 mL | 22.5505 mL | 45.1009 mL | 56.3761 mL |
5 mM | 0.451 mL | 2.255 mL | 4.5101 mL | 9.0202 mL | 11.2752 mL |
10 mM | 0.2255 mL | 1.1275 mL | 2.255 mL | 4.5101 mL | 5.6376 mL |
50 mM | 0.0451 mL | 0.2255 mL | 0.451 mL | 0.902 mL | 1.1275 mL |
100 mM | 0.0226 mL | 0.1128 mL | 0.2255 mL | 0.451 mL | 0.5638 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Collagen proline hydroxylase inhibitor-1 is an antifibroproliferative agents.
- K-115 free base
Catalog No.:BCC5501
CAS No.:223645-67-8
- Tiadinil
Catalog No.:BCC8070
CAS No.:223580-51-6
- CPA inhibitor
Catalog No.:BCC1500
CAS No.:223532-02-3
- YM 58483
Catalog No.:BCC7817
CAS No.:223499-30-7
- ONO 4817
Catalog No.:BCC2375
CAS No.:223472-31-9
- GLP-2 (human)
Catalog No.:BCC5891
CAS No.:223460-79-5
- FG2216
Catalog No.:BCC6402
CAS No.:223387-75-5
- Polygalacic acid
Catalog No.:BCN5898
CAS No.:22338-71-2
- Grandifloric acid
Catalog No.:BCN4669
CAS No.:22338-69-8
- Grandiflorenic acid
Catalog No.:BCN4670
CAS No.:22338-67-6
- 9-Hydroxy-alpha-lapachone
Catalog No.:BCN5060
CAS No.:22333-58-0
- Methyl ferulate
Catalog No.:BCN4023
CAS No.:22329-76-6
- Collagen proline hydroxylase inhibitor
Catalog No.:BCC1494
CAS No.:223666-07-7
- Mirabegron (YM178)
Catalog No.:BCC3814
CAS No.:223673-61-8
- Eupatilin
Catalog No.:BCN2336
CAS No.:22368-21-4
- 4-Methoxysalicylic acid
Catalog No.:BCN7783
CAS No.:2237-36-7
- Sodium Monensin
Catalog No.:BCC5319
CAS No.:22373-78-0
- NPE-caged-HPTS
Catalog No.:BCC5950
CAS No.:223759-19-1
- Bestatin trifluoroacetate
Catalog No.:BCC3909
CAS No.:223763-80-2
- Pedalitin
Catalog No.:BCN3954
CAS No.:22384-63-0
- Serratenediol
Catalog No.:BCN5061
CAS No.:2239-24-9
- 3,8-Di-O-methylellagic acid
Catalog No.:BCN5062
CAS No.:2239-88-5
- Aristola-1(10),8-dien-2-one
Catalog No.:BCN7608
CAS No.:22391-34-0
- Cyclobuxine D
Catalog No.:BCC9221
CAS No.:2241-90-9
Specific inhibition of eIF-5A and collagen hydroxylation by a single agent. Antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries.[Pubmed:7860726]
J Clin Invest. 1995 Feb;95(2):446-55.
Restenosis occurs in 35% of patients within months after balloon angioplasty, due to a fibroproliferative response to vascular injury. These studies describe a combined fibrosuppressive/antiproliferative strategy on smooth muscle cells cultured from human primary atherosclerotic and restenotic coronary arteries and from normal rat aortas. L-Mimosine suppressed the posttranslational hydroxylation of the precursors for collagen and for eukaryotic initiation factor-5A (eIF-5A) by directly inhibiting the specific protein hydroxylases involved, prolyl 4-hydroxylase (E.C. 1.14.11.2) and deoxyhypusyl hydroxylase (E.C. 1.14.99.29), respectively. Inhibition of deoxyhypusyl hydroxylation correlated with a dose-dependent inhibition of DNA synthesis. Inhibition of prolyl hydroxylation caused a dose-dependent reduction in the secretion of hydroxyproline-containing protein and decreased the formation of procollagen types I and III. The antifibroproliferative action could not be attributed to nonspecific or toxic effects of mimosine, appeared to be selective for the hydroxylation step in the biosynthesis of the procollagens and of eIF-5A, and was reversible upon removal of the compound. The strategy of targeting these two protein hydroxylases has important implications for the pathophysiology of restenosis and for the development of agents to control fibroproliferative diseases.
Induction of plasminogen activator inhibitor I gene expression by intracellular calcium via hypoxia-inducible factor-1.[Pubmed:15328163]
Blood. 2004 Dec 15;104(13):3993-4001.
The plasminogen activator inhibitor-1 (PAI-1) expression can be enhanced by hypoxia and other stimuli leading to the mobilization of intracellular calcium. Thus, it was the aim of the present study to investigate the role of calcium in the hypoxia-dependent PAI-1 expression. It was shown that the Ca(2+)-ionophore A23187 and the cell permeable Ca(2+)-chelator BAPTA-am (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester) induced PAI-1 mRNA and protein expression under normoxia and hypoxia in HepG2 cells. Transfection experiments with wild-type and hypoxia response element (HRE)-mutated PAI promoter constructs revealed that the HRE binding hypoxiainducible factor-1 (HIF-1) mediated the response to A23187 and BAPTA-am. Although A23187 induced a striking and stable induction of HIF-1alpha, BAPTA-am only mediated a fast and transient increase. By using actinomycin D and cycloheximide we showed that A23187 induced HIF-1alpha mRNA expression, whereas BAPTA-am acted after transcription. Although A23187 activated extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK), as well as protein kinase B, it appeared that the enhancement of HIF-1alpha by A23187 was only mediated via the ERK pathway. By contrast, BAPTA-am exerted its effects via inhibition of HIF-prolyl hydroxylase activity and von Hippel-Lindau tumor repressor protein (VHL) interaction. Thus, calcium appeared to have a critical role in the regulation of the HIF system and subsequent activation of the PAI-1 gene expression.